Full Text View
Tabular View
No Study Results Posted
Related Studies
N-Terminal Pro-Brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension
This study has been terminated.
( Interim analysis showed greater variablility in NT-proBNP findings than anticipated. )
First Received: March 2, 2007   Last Updated: May 1, 2009   History of Changes
Sponsors and Collaborators: Christiana Care Health Services
Thomas Jefferson University Hospital
Information provided by: Christiana Care Health Services
ClinicalTrials.gov Identifier: NCT00443859
  Purpose

Babies who are suspected of having persistent pulmonary hypertension (PPHN) will be included in this study. PPHN is a condition in which the blood is restricted from flowing to the lungs in a normal way making it hard for babies to breath and placing strain on the heart. This study will observe whether certain hormones that measure stress (N-terminal pro-brain natriuretic peptide) can help determine how well a baby will do when they have PPHN.


Condition
Persistent Pulmonary Hypertension of Newborn

MedlinePlus related topics: High Blood Pressure Pulmonary Hypertension
Drug Information available for: Nesiritide
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Clinical Significance of N-Terminal Pro-Brain Natriuretic Peptide Levels in Persistent Pulmonary Hypertension

Further study details as provided by Christiana Care Health Services:

Biospecimen Retention:   Samples Without DNA

Biospecimen Description:

Whole blood


Enrollment: 10
Study Start Date: February 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
PPHN
Infants with persistent pulmonary hypertension (PPHN)

Detailed Description:

PPHN occurs in infant > or = 34 weeks gestation and is characterized by an elevation in pulmonary vascular resistance (PVR) and right-to-left shunting of the blood at the atrial, ductal, and pulmonary levels, leading to hypoxemia. Management of these infants is complex (and the clinical course) is often difficult to predict.

Brain natriuretic peptide (BNP) is a cardiac hormone that is secreted from cardiac myocytes and cardiac fibroblasts. Upon activation, the prohormone is cleaved into a biologically active BNP and an inactive N-terminal proBNP (NT-proBNP). BNP and NT-proBNP levels are increasingly being used for diagnostic purpose in adults and have been correlated to adult pulmonary hypertension. Multiples studies have been performed to determine normal values for NT-proBNP in the pediatric population. One study measured NT-proBNP levels in umbilical cord blood during the second trimester and at delivery of uncomplicated pregnancies and determined normal reference values of NT-proBNP. It is thought that NT-proBNP has potential for use in term infants with PPHN.

The objective of this research is to correlate NT-proBNP levels to left ventricular dysfunction in term infants with PPHN. Secondarily, we want to assess the possible use of NT-proBNP to predict response to inhaled nitric oxide and the ability to successfully wean off inhaled nitric oxide.

  Eligibility

Ages Eligible for Study:   up to 6 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

All infants who are admitted to the NICU with a diagnoses of PPHN.

Criteria

Inclusion Criteria:

  • >/= 34 weeks gestation at birth
  • clinical diagnosis of PPHN

Exclusion Criteria:

  • newborns with evidence of structural heart disease, congenital anomalies and prior use of inhaled nitric oxide.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00443859

Locations
United States, Delaware
Christiana Hospital
Newark, Delaware, United States, 19718
United States, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania, United States, 19107
Sponsors and Collaborators
Christiana Care Health Services
Thomas Jefferson University Hospital
Investigators
Principal Investigator: Euming Chong, MD Christiana Hospital / Thomas Jefferson University Hospital
Principal Investigator: Constance Andrejko, DO Christiana Hospital / Thomas Jefferson University Hospital
  More Information

No publications provided

Responsible Party: Christiana Hospital / Thomas Jefferson University Hospital ( Euming Chong, MD )
Study ID Numbers: CCC 27004
Study First Received: March 2, 2007
Last Updated: May 1, 2009
ClinicalTrials.gov Identifier: NCT00443859     History of Changes
Health Authority: United States: Institutional Review Board

Keywords provided by Christiana Care Health Services:
Persistent Pulmonary Hypertension
N-terminal pro brain natriuretic peptide

Study placed in the following topic categories:
Natriuretic Peptide, Brain
Respiratory Tract Diseases
Hypertension, Pulmonary
Lung Diseases
Vascular Diseases
Persistent Fetal Circulation Syndrome
Infant, Newborn, Diseases
Cardiovascular Agents
Hormones
Hypertension

Additional relevant MeSH terms:
Natriuretic Peptide, Brain
Physiological Effects of Drugs
Vascular Diseases
Cardiovascular Agents
Pharmacologic Actions
Respiratory Tract Diseases
Hypertension, Pulmonary
Natriuretic Agents
Therapeutic Uses
Lung Diseases
Persistent Fetal Circulation Syndrome
Infant, Newborn, Diseases
Cardiovascular Diseases
Hypertension

ClinicalTrials.gov processed this record on May 07, 2009